Our team is committed to improving the clinical information available to healthcare providers and patients in making informed decisions on the use of the right drug, at the right time, in the right patient, with the right effect – personalization of medicine.
Janssen Diagnostics was established in February 2012 within Janssen Pharmaceuticals R&D, bringing together personnel with diverse healthcare experiences, skills and knowledge across diagnostics, pharmaceuticals and health information technologies from the former Virco, Veridex and Companion Diagnostics Centre of Excellence. We are a global company, based in Beerse, Belgium and Raritan, New Jersey, United States, and employ around 150 professionals from R&D to commercial roles.
We believe healthcare today and tomorrow is about improving outcomes for patients via innovative technologies and effective collaborations that put the patient at the centre, and derive clinical insights from complex information when it makes the most difference.
The strategy of Janssen Diagnostics is to innovate within personalized medicine by developing and commercializing diagnostics and health IT that support treatment decisions in our five major therapeutic areas (e.g. infectious diseases; oncology; neuroscience; cardiovascular and metabolism; and immunology).
Our focus is on initiatives that will develop diagnostics linked to the use of a drug within its approved label (companion diagnostics) and diagnostics or information tools that support disease management, around the use of a drug or drug regimens (complementary diagnostics). Our interest in health information tools support real-world data access and insights to help better manage individual patients and/or cohorts of patients.
Recognizing the diversity and complexity of advancing personalized healthcare solutions our business model is predominantly partnership driven to ensure wide access to our diagnostic solutions globally. Consequently, we continuously look for opportunities to discuss potential areas of common interest with researchers, academia and industry partners.
We look forward to collaborating with you as we strive towards our mutual goal of improving and prolonging patients’ lives.